KRAS-mutant pancreatic cancer: a multicenter database for targeted therapy
Official title: Construction and Maintenance of a Precision Subtyping-Based Clinical Cohort for Targeted Therapy in KRAS-Mutant Pancreatic Cancer
Run by Fudan University · NCT07557849 · Data updated 2026-11-12
This project builds a real-world, multicenter cohort to see how well KRAS-targeted therapies work for people with pancreatic cancer who have KRAS mutations.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | May 22, 2026 |
| Main results expected | April 30, 2028 |
| Study ends | April 30, 2029 |
| Registry record updated | May 26, 2026 |
| Trial ID | NCT07557849 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with pathologically confirmed pancreatic adenocarcinoma, known KRAS mutation subtype, and prior or ongoing KRAS-targeted therapy who can adhere to study visits.
✕Probably not a fit
Patients without a KRAS mutation or those not receiving KRAS-targeted therapy may not benefit from the findings of this cohort.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational effort creates a prospective cohort of KRAS-mutant pancreatic cancer patients who have received KRAS-targeted therapies, aiming to generate a comprehensive database that links clinical practice with research. The study collects data on treatment patterns, safety, and outcomes to inform precision medicine approaches. It emphasizes real-world evidence across a network of centers led by Fudan University, with standardized visit schedules and data collection. The goal is to understand heterogeneity in response by KRAS subtype and patient factors, guiding clinical decision-making. No interventional protocol is described in detail within this summary.
Why it matters
Potential benefit: If successful, the cohort could clarify which KRAS-targeted approaches are most effective for specific KRAS subtypes in pancreatic cancer and help personalize treatment decisions.
How similar studies have gone: Prior studies in KRAS-targeted approaches have shown variable results; this project adds a real-world, multicenter data layer but its success will depend on data quality and heterogeneity.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* No restrictions on age, gender, or performance status score;
* Pathologically or cytologically confirmed pancreatic adenocarcinoma; ③ Known KRAS mutation subtype and has received treatment with KRAS-targeted agents;
④ Able to comply with the study visit schedule requirements;
⑤ Voluntarily participate and sign the informed consent form.
Exclusion Criteria:
* Non-neoplastic pancreatic lesions;
* Non-primary pancreatic neoplastic lesions; ③ Unable to comply with the study visit schedule requirements; ④ Refuse to participate and sign the informed consent form.
Where it's running
-
Department of Pancreatic Surgery
Shanghai, China Recruiting
Study contacts
- Principal investigator: Guopei Luo — Fudan University
- Study coordinator: Yi Liu, MD
- Email: liuyi@fudanpci.org
- Phone: 86 21-64175590
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
-
Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer
This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.
-
Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer
This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.
-
Blood protein biomarkers to help diagnose pancreatic cancer in adults
This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.
-
Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)
This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.